Until now, SMA in India was curable only with the two most expensive and imported gene therapies -- Spinraza and Zolgensma -- from Biogen-Ionis and Novartis. Treatment for SMA costs over Rs 16-18 crore in India
As part of second-quarter financial results released on Thursday, the approvals timetable indicates a USFDA approval application for COVID-19 Vaccine AstraZeneca SARS-CoV-2 (US) later in the year
According to a statement issued by Brazil's National Health Surveillance Agency, Anvisa, its Collegiate Board on Tuesday decided to suspend the authorisation for import and distribution of Covaxin in the country after Bharat Biotech informed the South American government about the termination of its pact with its Brazilian partners
The company benefited from strong demand during the pandemic, but rising vaccination has hit demand for these tests and other test makers have also warned of a slump
The researchers from University College London (UCL) in the UK noted that if the antibody levels carry on dropping at this rate, there are concerns that the protective effects of the vaccines may also begin to wear off, particularly against new variants
The company had posted a net profit of Rs 110.83 crore for the corresponding period of the previous fiscal, GlaxoSmithKline Pharmaceuticals said in a regulatory filing
"The vaccines for children should come out now because trials in India are already there in the vaccines which are available in India, the Bharat Biotech trial is in the final phase by September we will have the data," Dr Guleria told ANI
The Centre is still holding discussions with the US-based pharma company regarding the production of its mRNA technology-based COVID-19 vaccine as part of the country's vaccination programme
Bharat's statement said it will continue to work with Brazilian healthcare regulator Anvisa to obtain all required approvals for the use of Covaxin in the country
Biovac has been appointed to manufacture the Pfizer-BioNTech COVID-19 vaccine for distribution within Africa, making it the first company on the continent to produce an mRNA-based vaccine
Prakash Kumar Singh, Director, Government and Regulatory Affairs at Pune-based SII, in a letter, referred to a gazette notification by the Union Health Ministry on May 18, 2020
